Seven Eight Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Seven Eight Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,793	Closed	-$1.61M	–	782
2021 Q2	$1.61M	Sell	8,793 -20,020	-69%	-$3.44M	0.23%	139
2021 Q1	$4.5M	Hold	28,813	–	–	1.03%	2
2020 Q4	$4.5M	Buy	+28,813	New	+$3.7M	1.02%	2
2020 Q3	–	Sell	-2,213	Closed	-$248K	–	682
2020 Q2	$248K	Sell	2,213 -19,887	-90%	-$2.11M	0.18%	227
2020 Q1	$1.98M	Buy	22,100 +7,093	+47%	+$696K	0.51%	49
2019 Q4	$1.62M	Sell	15,007 -65,297	-81%	-$6.98M	0.09%	349
2019 Q3	$7.87M	Buy	80,304 +20,602	+35%	+$2.32M	0.42%	60
2019 Q2	$7.82M	Buy	+59,702	New	+$7.69M	0.41%	65
2019 Q1	–	Sell	-126,402	Closed	-$12.3M	–	774
2018 Q4	$12.3M	Buy	126,402 +119,300	+1,680%	+$14.1M	0.69%	32
2018 Q3	$987K	Buy	+7,102	New	+$891K	0.06%	361
2018 Q2	–	Sell	-37,752	Closed	-$4.21M	–	620
2018 Q1	$4.21M	Buy	37,752 +15,600	+70%	+$1.86M	0.35%	115
2017 Q4	$2.65M	Buy	+22,152	New	+$2.7M	0.27%	131
2017 Q3	–	Sell	-452	Closed	-$55K	–	668
2017 Q2	$55K	Sell	452 -1,057	-70%	-$123K	0.01%	479
2017 Q1	$183K	Buy	+1,509	New	+$195K	0.04%	369
2016 Q3	–	Sell	-10,903	Closed	-$1.27M	–	601
2016 Q2	$1.27M	Buy	+10,903	New	+$1.55M	0.44%	66
2015 Q2	–	Sell	-3,000	Closed	-$520K	–	707
2015 Q1	$520K	Buy	+3,000	New	+$543K	0.87%	17

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Seven Eight Capital's ALXN Position: Q3 2021 in Review

Seven Eight Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 8,793 shares — an estimated $1.61M sold.

Seven Eight Capital first reported a position in ALXN in Q1 2015 and held it in 16 quarters. The position peaked at $12.3M in Q4 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Seven Eight Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Seven Eight Capital sold 8,793 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.61M.
Seven Eight Capital first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 16 quarters.
Seven Eight Capital's Alexion Pharmaceuticals position peaked at $12.3M in Q4 2018.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Seven Eight Capital's 13F filing for Q3 2021, filed 15 Nov 2021.